Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Investor Presentation (October 2026)
27 slides from Ac Immune Sa's investor presentation, October 2026
Slide 1: Pioneering Medicines for Neurodegenerative Diseases
PIONEERING MEDICINES FOR NEURODEGENERATIVE DISEASES Investor Presentation NASDAQ: ACIU | October 2026 NASDAQ: ACIU | Investor Presentation, October 2026 © 2026 AC Immune. Not to be used or reproduced without permission
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include s
Slide 3: AC Immune – targeting key pathologic misfolded proteins and pathways
AC Immune – targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases Focused pipeline: extensively validated neurodegenerative ■ Based in Lausanne, Switzerland disease pipeline ■ ~120 employees ■ Listed on NASDAQ: ACIU Deep expertise based on two decades of
Slide 4: Validation from multiple pharmaceutical partners across proprietary platforms and modalities
Validation from multiple pharmaceutical partners across proprietary platforms and modalities Modality Candidate Partner Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 ACI-7104 Parkinson’s disease (a-syn1) FDA Fast Track Immunotherapy Alzheimer's disease (Abeta2) FDA Fast Track Active ACI-2
Slide 5: Key milestones 2026
Key milestones 2026 Readouts Multiple catalysts across pipeline Other development events Active immunotherapies H1 2026 H2 2026 ABATE Phase 2 trial in AD1: first patient dosed in AD4 cohort ACI-24 (Takeda) Abeta ABATE Phase 2 trial results after 12 months of treatment Submissions to regulators regar
Slide 6: Positive Safety & Immunogenicity in Part 1 of VacSYn Phase 2 Trial
Positive Safety & Immunogenicity in Part 1 of VacSYn Phase 2 Trial Randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with early-stage Parkinson’s disease. 34 patients (25 receiving ACI-7104 and nine receiving placebo). ACI-7104 Met primary Robust antibody Exploratory
Slide 7: Parkinson's disease
Parkinson’s disease Pathological deposition of alpha-synuclein Most common neurodegenerative movement disorder Main component of Lewy bodies: Alpha-synuclein Affects ~1% of the population over 65 years Halliday et al. 2011 Etiology 5-10% genetic, 90-95% idiopathic, unknown cause Cardinal motor sympt
Slide 8: Adaptive Phase 2 study of ACI-7104 in early PD
: Adaptive Phase 2 study of ACI-7104 in early PD1 Placebo-controlled biomarker-based Phase 2 Study Overview (clinicaltrials.gov identifier: NCT06015841) Part 1: Safety & Immunogenicity Treatment Follow-up (18 months) (6 months) Analysis 25 active ▪ Primary outcome measures: Randomization 3:1 ▪ Safet
Slide 9: Safety/tolerability findings: No safety concerns raised by DSMB
: Safety/tolerability findings: No safety concerns raised by DSMB1 Baseline profile Unit Total2 Overall good benefit/risk to date. Total number of patients n 34 Age Years mean (std) 62.1 (6.7) DSMB consistently recommended that the trial Sex Male n (%) 22 (65%) Female n (%) 12 (35%) may continue wit
Slide 10: ACI-7104 induces robust antibody response in early PD
ACI-7104 induces robust antibody response in early PD1 100% responder rate observed for anti-PD012 antibody titers in serum Mean antibody titers in serum3 ACI-7104 Placebo ▪ All participants exhibited anti-PD01 IgG4 antibodies in serum (from week 14) ▪ Antibody responses were boosted after each dose
Slide 11: Antibody titers in CSF increase with successive immunizations
Antibody titers in CSF1 increase with successive immunizations ACI-7104 generates antibodies against modified a-syn that cross the blood-brain barrier Mean anti-PD012 antibody titers3 in CSF ACI-7104 Placebo ▪ On average, IgG4 antibody levels in CSF were an order of magnitude higher after the 6th im
Slide 12: Exploratory correlation analysis: antibody titers in relation to MDS-UPDRS III
Exploratory correlation analysis: antibody titers in relation to MDS-UPDRS III Correlation of anti-PD01 IgG titers FCBL1 and MDS-UPDRS Part III CBL2 at week 74 (end of treatment) Correlation between anti-PD01 IgG titers in serum (Fold Change from Baseline) and MDS-UPDRS III (Change from Baseline) at
Slide 13: Summary – ACI-7104 Part 1 results support further development
Summary – ACI-7104 Part 1 results support further development ▪ ACI-7104 was safe and induced significant antibody levels with robust antibody penetration into the cerebrospinal fluid (CSF) observed in all treated participants ▪ Antibody reactivity against the aggregated species of a-syn was observe
Slide 14: Adaptive Phase 2 study of ACI-7104 in early PD
: Adaptive Phase 2 study of ACI-7104 in early PD1 Placebo-controlled biomarker-based Phase 2 Study Overview (clinicaltrials.gov identifier: NCT06015841) Part 1: Safety & Immunogenicity - extension Treatment Follow-up Extension (18 months) (6 months) (up to 24 months) 25 active Randomization 3:1 9 pl
Slide 15: Outlook – ACI-7104 moving into expanded Phase 2
Outlook – ACI-7104 moving into expanded Phase 2 ▪ Objective to demonstrate clinical activity as the basis for Phase 3 ▪ Part 2 of VacSYn Phase 2 study designed with optimized inclusion criteria (N~250 patients), 24-month treatment period, and enhanced clinical outcome measures: ➢ Digital measures of
Slide 16: ACI-24 for early-stage Alzheimer's disease
ACI-24 for early-stage Alzheimer’s disease ACI-7104 ACI-24 ACI-35 Intracellular anti-a-syn anti-Abeta anti-pTau targeting Active immunotherapy Biomarker-driven The only active Small molecule programs targeting pathological development targeting the immunotherapy in a targeting intracellular a-syn in
Slide 17: Biomarker-based Phase 1b/2 study of ACI-24 in AD and DS
: Biomarker-based Phase 1b/2 study of ACI-24 in AD1 and DS2 Placebo-controlled Phase 1b/2 Study Overview Trial Schematic Dose escalation in AD Follow up / expansion phase in AD Adaptive Study Design ▪ Interim analyses of safety/tolerability & immunogenicity Treatment in AD4 Both Follow up ▪ Biomarke
Slide 18: ACI-35 for pre-symptomatic Alzheimer's disease
ACI-35 for pre-symptomatic Alzheimer’s disease ACI-7104 ACI-24 ACI-35 Intracellular anti-a-syn anti-Abeta anti-pTau targeting Active immunotherapy Biomarker-driven The only active Small molecule programs targeting pathological development targeting the immunotherapy in a targeting intracellular a-sy
Slide 19: Phase 2 study of ACI-35 (JNJ-2056) in preclinical AD
Reain 2* : Phase 2 study of ACI-35 (JNJ-2056) in preclinical AD1 A randomized, multicenter, double-blind, placebo-controlled Phase 2 study Study population Biomarker readouts Cognitive endpoints ▪ ~60 participants with preclinical AD: ▪ Tau pathology compared with placebo: ▪ Preclinical AD Cognitiv
Slide 20: AC Immune's small molecule programs targeting intracellular pathology
AC Immune’s small molecule programs targeting intracellular pathology ACI-7104 ACI-24 ACI-35 Intracellular anti-a-syn anti-Abeta anti-pTau targeting Active immunotherapy Biomarker-driven The only active Orally administered small targeting pathological development targeting the immunotherapy in a mol
Slide 21: Tau-targeted Morphomers: in vivo activity in aggressive model of Tau pathology
1 Tau-targeted Morphomers®: in vivo activity in aggressive model of Tau pathology1 HMW soluble Tau Soluble HMW Tau aggregates ▪ Tau-targeting Morphomers® halt pathology in preclinical model at multiple points (1)Tg4510 model NASDAQ: ACIU | Investor Presentation, October 2026 © 2026 AC Immune. Not to
Slide 22: a-syn-targeted Morphomers to address a-syn pathologies
2 1 a-syn -targeted Morphomers to address a-syn pathologies Unique small molecule assets including therapeutics and diagnostics ▪ Small molecule Morphomer® targets intracellular pathological a-syn aggregates to treat and prevent Parkinson’s disease ▪ Lead candidate decision anticipated in H2 2026 Mo
Slide 23: NLRP3 inhibitor, ACI-19764, small molecule targeting inflammation
3 NLRP31 inhibitor, ACI-19764, small molecule targeting inflammation Preliminary Phase 1 findings High potency - preclinical High selectivity - preclinical ▪ Generally safe and well tolerated in IL-1β 3 inhibition IC50 ▪ No action on other inflammasomes4 healthy volunteers Human macrophages 2 nM ▪ O
Slide 24: Key milestones 2026
Key milestones 2026 Readouts Multiple catalysts across pipeline Other development events Active immunotherapies H1 2026 H2 2026 ABATE Phase 2 trial in AD1: first patient dosed in AD4 cohort ACI-24 (Takeda) Abeta ABATE Phase 2 trial results after 12 months of treatment Submissions to regulators regar
Slide 25: Selectively targeting the key pathologic misfolded proteins and pathways
Selectively targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases NASDAQ: ACIU | Investor Presentation, October 2026 © 2026 AC Immune. Not to be used or reproduced without permission 25
Slide 26: Supplementary information
Supplementary information
Slide 27: AC Immune's strong track record in deals with leading pharma companies
AC Immune’s strong track record in deals1 with leading pharma companies Strategy: optimize value to risk ratio and retain significant upside Milestones Program Phase Total value2 Upfront2 Royalties Partner received2 ACI-24 Phase 1b/2 >USD 2,100 USD 100 USD 12 Mid-to-high teens (anti-Abeta active imm